Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00914212 | A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103) | PHASE1 | COMPLETED | 15 | — | — | May 1, 2009 | Aug 1, 2009 | Oct 12, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Sibutramine |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Single dose placebo to sibutramine in two of three treatment periods. |
| Comparator: sibutramine | DRUG | Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods. |
Inclusion Criteria: * Subject is a male between 18 and 45 years of age * Subject has a body mass index (BMI) between 28 and 35 kg/m\^2 * Subject does not weigh more than 140 kg (309 lbs) at the screening visit * Subject is right-handed * Subject is a non-smoker * Subject is in generally good health...